Back to top

Image: Bigstock

A Dive into Hologic (HOLX) International Revenue Trends and Forecasts

Read MoreHide Full Article

Did you analyze how Hologic (HOLX - Free Report) fared in its international operations for the quarter ending March 2024? Given the widespread global presence of this medical device maker, scrutinizing the trends in international revenues becomes imperative to assess its financial strength and future growth possibilities.

The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and growth path. It has become essential for investors to comprehend how much a company relies on these foreign markets, as this understanding reveals the firm's potential for consistent earnings, its capacity to harness different economic cycles, and its overall growth prospects.

Being present in international markets serves as a counterbalance to domestic economic challenges while offering chances to engage with more rapidly evolving economies. However, this kind of diversification introduces challenges like currency fluctuations, geopolitical uncertainties and varying market trends.

While delving into HOLX's performance for the past quarter, we observed some fascinating trends in the revenue from its foreign segments that are commonly modeled and observed by analysts on Wall Street.

The recent quarter saw the company's total revenue reaching $1.02 billion, marking a decline of 0.9% from the prior-year quarter. Next, we'll examine the breakdown of HOLX's revenue from abroad to comprehend the significance of its international presence.

A Dive into HOLX's International Revenue Trends

Europe generated $137 million in revenues for the company in the last quarter, constituting 13.5% of the total. This represented a surprise of +6% compared to the $129.24 million projected by Wall Street analysts. Comparatively, in the previous quarter, Europe accounted for $142.8 million (14.1%), and in the year-ago quarter, it contributed $151.5 million (14.8%) to the total revenue.

During the quarter, Rest of World contributed $57 million in revenue, making up 5.6% of the total revenue. When compared to the consensus estimate of $53.42 million, this meant a surprise of +6.7%. Looking back, Rest of World contributed $52.8 million, or 5.2%, in the previous quarter, and $41.1 million, or 4%, in the same quarter of the previous year.

Asia-Pacific accounted for 6.3% of the company's total revenue during the quarter, translating to $64.4 million. Revenues from this region represented a surprise of -0.29%, with Wall Street analysts collectively expecting $64.59 million. When compared to the preceding quarter and the same quarter in the previous year, Asia-Pacific contributed $63.8 million (6.3%) and $65.2 million (6.4%) to the total revenue, respectively.

Prospective Revenues in International Markets

The current fiscal quarter's total revenue for Hologic, as projected by Wall Street analysts, is expected to reach $1 billion, reflecting an increase of 1.7% from the same quarter last year. The breakdown of this revenue by foreign region is as follows: Europe is anticipated to contribute 12.4% or $124.25 million, Rest of World 5.6% or $56.47 million and Asia-Pacific 6.5% or $64.6 million.

For the full year, a total revenue of $4.04 billion is expected for the company, reflecting an increase of 0.2% from the year before. The revenues from Europe, Rest of World and Asia-Pacific are expected to make up 12.9%, 5.5% and 6.4% of this total, corresponding to $519.65 million, $222.87 million and $258.16 million respectively.

Closing Remarks

Hologic's leaning on foreign markets for its revenue stream presents a mix of chances and challenges. Therefore, a vigilant watch on its international revenue movements can greatly aid in projecting the company's future direction.

In a world where international interdependencies and geopolitical conflicts are ever-increasing, Wall Street analysts closely monitor these trends for companies having international presence to adjust their earnings forecasts. Of course, there are several other factors, including a company's standing within its home borders, that influence analysts' earnings forecasts.

Here at Zacks, we put a great deal of emphasis on a company's changing earnings outlook, as empirical research has shown that's a powerful force driving a stock's near-term price performance. Quite naturally, the correlation is positive here -- an upward revision in earnings estimates drives the stock price higher.

Boasting a remarkable track record that's been externally verified, the Zacks Rank, our unique stock rating system, leverages changes in earnings projections to function as a reliable gauge for predicting short-term stock price movements.

Hologic currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Exploring Recent Trends in Hologic's Stock Price

Over the past month, the stock has lost 1.9% versus the Zacks S&P 500 composite's 0.4% decrease. The Zacks Medical sector, of which Hologic is a part, has declined 0.6% over the same period. The company's shares have increased 2.5% over the past three months compared to the S&P 500's 4.9% increase. Over the same period, the sector has declined 2.1%.

See More Zacks Research for These Tickers

Normally $25 each - click below to receive one report FREE:

Hologic, Inc. (HOLX) - free report >>

Published in